NASDAQ:BBLG Bone Biologics (BBLG) Stock Price, News & Analysis → Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem (From Weiss Ratings) (Ad) Free BBLG Stock Alerts $1.66 +0.11 (+7.10%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$1.56▼$1.6650-Day Range$1.46▼$2.3052-Week Range$1.38▼$55.12Volume47,541 shsAverage Volume101,294 shsMarket Capitalization$1.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Bone Biologics alerts: Email Address Bone Biologics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.59Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.32) to ($4.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.63 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Bone Biologics.Read more about Bone Biologics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.60% of the float of Bone Biologics has been sold short.Short Interest Ratio / Days to CoverBone Biologics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bone Biologics has recently decreased by 7.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBone Biologics does not currently pay a dividend.Dividend GrowthBone Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BBLG. Previous Next 3.7 News and Social Media Coverage News SentimentBone Biologics has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bone Biologics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Bone Biologics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bone Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders13.00% of the stock of Bone Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.30% of the stock of Bone Biologics is held by institutions.Read more about Bone Biologics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bone Biologics are expected to grow in the coming year, from ($5.32) to ($4.84) per share.Price to Book Value per Share RatioBone Biologics has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bone Biologics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Bone Biologics Stock (NASDAQ:BBLG)Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.Read More BBLG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BBLG Stock News HeadlinesMay 16, 2024 | finance.yahoo.comBBLG Continues Progress as Testing ProceedsMarch 6, 2024 | businesswire.comBone Biologics Announces Closing of $2.0 Million Public OfferingMarch 4, 2024 | businesswire.comBone Biologics Announces Pricing of $2.0 Million Public OfferingMarch 1, 2024 | businesswire.comBone Biologics Reports Progress With NB1 Clinical ProgramJanuary 10, 2024 | finance.yahoo.comBone Biologics Regains Compliance with Nasdaq Continued Listing RequirementsDecember 28, 2023 | benzinga.comTrump-Linked SPAC Digital World Acquisition, Bone Biologics, Redwood Trust, Baidu, Tesla — Why These 5 Stocks Are On Investors' Radars TodaySee More Headlines Receive BBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bone Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/31/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNASDAQ:BBLG Previous SymbolNASDAQ:BBLG CUSIPN/A CIK1419554 Webwww.bonebiologics.com Phone781-552-4452FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-151.99% Return on Assets-121.03% Debt Debt-to-Equity RatioN/A Current Ratio23.33 Quick Ratio23.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book0.47Miscellaneous Outstanding Shares1,100,000Free Float957,000Market Cap$1.72 million OptionableNot Optionable Beta0.24 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Jeffrey Frelick (Age 58)CEO & President Comp: $325kMs. Deina H. Walsh (Age 60)Chief Financial Officer Comp: $212.5kDr. Shun'ichi KurodaCo-Founder & Member of Scientific Advisory BoardKey CompetitorsHeart Test LaboratoriesNASDAQ:HSCSNanoVibronixNASDAQ:NAOVLogicMarkNASDAQ:LGMKSientraNASDAQ:SIENQAllied Healthcare ProductsNASDAQ:AHPIView All CompetitorsInsidersDeina H WalshBought 1,000 shares on 9/13/2023Total: $5,120.00 ($5.12/share)Jeff FrelickBought 1,187 shares on 9/11/2023Total: $6,552.24 ($5.52/share)Deina H WalshBought 875 shares on 9/6/2023Total: $4,970.00 ($5.68/share)Jeff FrelickBought 950 shares on 8/31/2023Total: $5,016.00 ($5.28/share)View All Insider Transactions BBLG Stock Analysis - Frequently Asked Questions How have BBLG shares performed in 2024? Bone Biologics' stock was trading at $4.52 at the beginning of 2024. Since then, BBLG shares have decreased by 63.3% and is now trading at $1.66. View the best growth stocks for 2024 here. Are investors shorting Bone Biologics? Bone Biologics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 18,300 shares, a decline of 7.1% from the April 30th total of 19,700 shares. Based on an average daily trading volume, of 104,300 shares, the short-interest ratio is currently 0.2 days. Currently, 3.6% of the company's shares are short sold. View Bone Biologics' Short Interest. When is Bone Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our BBLG earnings forecast. How were Bone Biologics' earnings last quarter? Bone Biologics Co. (NASDAQ:BBLG) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.60) by $6.29. When did Bone Biologics' stock split? Bone Biologics's stock reverse split before market open on Wednesday, December 20th 2023. The 1-8 reverse split was announced on Wednesday, December 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Bone Biologics IPO? Bone Biologics (BBLG) raised $8 million in an initial public offering (IPO) on Wednesday, October 13th 2021. The company issued 1,510,455 shares at a price of $5.25 per share. How do I buy shares of Bone Biologics? Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BBLG) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarGold Set to EXPLODE!Gold Safe ExchangeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTradeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bone Biologics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.